Sartorius Stedim Biotech: Fact Sheet on New Reporting Format

Sartorius Stedim Biotech: Fact Sheet on New Reporting Format

AUBAGNE, France & GOETTINGEN, Germany--(BUSINESS WIRE)-- From the first quarter of 2013 onwards, Sartorius Stedim Biotech (Paris:DIM) will adopt a few slight changes to its reporting in order to follow established international reporting practice and thus to provide financial data in the best comparable manner. Relevant changes relate to amortization as well as to other taxes, which are now shown under functional expenses. Moreover, going forward underlying EBITDA will be used as the key performance indicator instead of underlying EBITA, which has been used so far. However, these changes to cost allocations do not influence the net result of the group. This fact sheet translates Sartorius Stedim Biotech's business figures for 2012 as well as its earnings guidance for 2013 according to these changes.

Sartorius Stedim

in millions of € unless otherwise specified  
 3-mo. 2012 6-mo. 2012 9-mo. 2012FY 2012
Sales revenue133.5272.6413.1544.0
Cost of sales-67.2-137.6-207.4-272.1
Gross profit on sales66.2134.9205.7271.9
Selling and distribution costs-30.1-60.1-90.1-119.4
Research and development costs-8.1-15.9-24.0-31.8
General administrative expenses-7.6-14.9-22.5-29.6
Other operating income and expenses-1.3-4.2-5.9-5.5
Earnings before interest and taxes (EBIT)19.239.963.285.6
Financial result0.5-2.7-1.0-3.7
Profit before taxes19.737.262.281.9
Income taxes | deferred taxes-5.9-11.2-18.7-24.0
Non-controlling interest-0.1-0.4-0.8-1.1
Net profit13.625.642.756.8
Extraordinary expenses1.
Underlying EBITA1)23.047.874.699.5
Underlying EBITA margin in %1)17.217.518.018.3
Underlying EBITDA1)26.956.187.2117.0
Underlying EBITDA margin in %1) 20.1 20.6 



Comparison of 2012 reported vs.
restated figures

in millions of € unless otherwise specified  
 FY 2012 reported Margin in % FY 2012 restatedMargin in %
Underlying EBITA1)101.118.699.518.3
Underlying EBITDA1) 118.6 21.8 117.0 21.5

Sartorius Stedim Biotech Earnings Guidance 2013


2013 guidance based on underlying
EBITA margin1)2)


2013 guidance based on underlying
EBITDA margin1)2)

 before restatementafter restatement
Sartorius Stedim Biotech ~ 19% ~ 22.5%

1) Adjusted for extraordinary items 2) in constant currencies

As of the first quarter of 2013, only guidance based on underlying EBITDA will be provided.

A profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, cell cultivation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of "turning science into solutions".

Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany. The company employs more than 3,000 people, and in 2012 earned sales revenue of 544.0 million euros.

Sartorius Corporate Administration GmbH
Petra Kirchhoff, +49(0)551/ 308-1686
Vice President of Group Corporate Communications
Fax: +49(0)551/ 308-3410

KEYWORDS:   Europe  France  Germany


The article Sartorius Stedim Biotech: Fact Sheet on New Reporting Format originally appeared on

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story